Journal Watch · Nature Chemical Biology · 2026

Complex-specific inhibitors for interrogating ATAC histone acetyltransferase complex.

This study not only sheds light on the regulatory roles of the ATAC HAT complex in gene transcription but also provides evidence that the chemical inhibition of the ATAC complex can be a promising therapeutic strategy.

Liu S, Liu J, Wu Y et al.Nature Chemical Biology3 min readPharma relevance 50/100

DOI: 10.1038/s41589-025-02132-7PMID: 41513852Study type: preclinical (animal / model) study

TL;DR

This study not only sheds light on the regulatory roles of the ATAC HAT complex in gene transcription but also provides evidence that the chemical inhibition of the ATAC complex can be a promising therapeutic strategy.

Key findings

  • The most effective inhibitor, LS-170, specifically reduced the chromatin occupancy of the ATAC complex, decreased the ATAC-dependent histone acetylation level and downregulated the expression of ATAC-governed genes, leading to significantly suppressed tumor growth in a lung cancer mouse model.
  • This study not only sheds light on the regulatory roles of the ATAC HAT complex in gene transcription but also provides evidence that the chemical inhibition of the ATAC complex can be a promising therapeutic strategy.

What they did

To understand the complex-dependent roles of HATs, we present a chemical approach to specifically dissociate ATAC (Ada-two-A-containing) HAT complex from chromatin without perturbing other complexes. Rather than targeting the shared HAT enzyme, we developed chemical inhibitors for an ATAC-specific subunit, YEATS2.

Full abstract (original)

Background: Histone acetyltransferases (HATs) modify chromatin to regulate gene expression. Instead of acting alone, HATs function in complexes with other proteins, leading to variations in substrate specificity, genomic localization and cellular function.

What they did: To understand the complex-dependent roles of HATs, we present a chemical approach to specifically dissociate ATAC (Ada-two-A-containing) HAT complex from chromatin without perturbing other complexes. Rather than targeting the shared HAT enzyme, we developed chemical inhibitors for an ATAC-specific subunit, YEATS2.

Results & conclusions: The most effective inhibitor, LS-170, specifically reduced the chromatin occupancy of the ATAC complex, decreased the ATAC-dependent histone acetylation level and downregulated the expression of ATAC-governed genes, leading to significantly suppressed tumor growth in a lung cancer mouse model. This study not only sheds light on the regulatory roles of the ATAC HAT complex in gene transcription but also provides evidence that the chemical inhibition of the ATAC complex can be a promising therapeutic strategy.

Abstract © the authors / Nature Chemical Biology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41589-025-02132-7 · PubMed 41513852.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Chemical Biology study find?

This study not only sheds light on the regulatory roles of the ATAC HAT complex in gene transcription but also provides evidence that the chemical inhibition of the ATAC complex can be a promising therapeutic strategy.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Chemical Biology in 2026. To understand the complex-dependent roles of HATs, we present a chemical approach to specifically dissociate ATAC (Ada-two-A-containing) HAT complex from chromatin without perturbing other complexes.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41589-025-02132-7. PubMed ID: 41513852. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Liu S, Liu J, Wu Y et al.. Complex-specific inhibitors for interrogating ATAC histone acetyltransferase complex.. Nature Chemical Biology (2026). DOI: 10.1038/s41589-025-02132-7.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/complex-specific-inhibitors-for-interrogating-atac-histone-acetyltransfe-021327/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides